Trial Profile
A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® in Comparison With Botox®, Assuming a Bioequivalence Ratio of 2.5:1 Units, in the Cervical Dystonia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- 16 Oct 2013 New trial record